CD8A and neoplasm: As previously demonstrated, CD8+ cells synchronously cultured in the presence of IL-2 plus IL-7 for 50 days and expanded to 108-fold demonstrated minimal efficacy against subcutaneous tumors (P = 0.39 versus control) with 1/5 mice achieving complete tumor regression.